Discovery and Targeting of the Signaling Controls of


Journal

Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052

Informations de publication

Date de publication:
07 10 2020
Historique:
received: 16 07 2020
revised: 01 10 2020
accepted: 05 10 2020
entrez: 10 10 2020
pubmed: 11 10 2020
medline: 5 8 2021
Statut: epublish

Résumé

Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are emerging worldwide epidemics, projected to become the leading cause of liver transplants. The strongest genetic risk factor for NAFLD/NASH susceptibility and progression is a single-nucleotide polymorphism (SNP) in the patatin-like phospholipase domain-containing 3 gene (

Identifiants

pubmed: 33036387
pii: cells9102247
doi: 10.3390/cells9102247
pmc: PMC7600576
pii:
doi:

Substances chimiques

PNPLA3 protein, mouse EC 3.1.1.3
Phospholipases A2, Calcium-Independent EC 3.1.1.4

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Références

Hepatology. 2016 Mar;63(3):787-98
pubmed: 26605757
Hepatology. 2017 Jun;65(6):1875-1890
pubmed: 28073161
J Biol Chem. 2001 Sep 7;276(36):33336-44
pubmed: 11431482
PLoS Genet. 2009 Feb;5(2):e1000337
pubmed: 19197355
Mol Metab. 2019 Apr;22:49-61
pubmed: 30772256
Invest New Drugs. 2019 Feb;37(1):159-165
pubmed: 30105668
Blood. 2010 Jun 24;115(25):5232-40
pubmed: 20385788
J Lipid Res. 2009 Oct;50(10):2111-6
pubmed: 19738004
Nat Rev Genet. 2013 Aug;14(8):549-58
pubmed: 23835440
Hum Mol Genet. 2016 Dec 1;25(23):5212-5222
pubmed: 27742777
Cells. 2019 Dec 05;8(12):
pubmed: 31817503
Nat Genet. 2008 Dec;40(12):1461-5
pubmed: 18820647
Hepatology. 2019 Jun;69(6):2427-2441
pubmed: 30802989
Hepatology. 2010 Apr;51(4):1209-17
pubmed: 20373368
Int J Mol Sci. 2019 Apr 02;20(7):
pubmed: 30986904
Nat Methods. 2017 Oct;14(10):959-962
pubmed: 28846090
Nat Rev Genet. 2016 Oct 14;17(11):661-678
pubmed: 27739532
J Hepatol. 2014 Jul;61(1):75-81
pubmed: 24607626
Proc Natl Acad Sci U S A. 2019 May 7;116(19):9521-9526
pubmed: 31019090
Hum Mol Genet. 2014 Aug 1;23(15):4077-85
pubmed: 24670599
Hepatology. 2010 Sep;52(3):894-903
pubmed: 20684021
Nat Protoc. 2006;1(2):729-48
pubmed: 17406303
J Clin Invest. 1998 Sep 1;102(5):910-8
pubmed: 9727059
Leukemia. 2009 Aug;23(8):1441-5
pubmed: 19295546
Blood. 2017 Mar 30;129(13):1823-1830
pubmed: 28188131
Hepatology. 2013 May;57(5):1763-72
pubmed: 23175050
Hepatology. 2010 Sep;52(3):904-12
pubmed: 20648472
J Biol Chem. 2011 Oct 28;286(43):37085-93
pubmed: 21878620
Cell Metab. 2020 Jan 7;31(1):35-45
pubmed: 31914377

Auteurs

Brian E Schwartz (BE)

CAMP4 Therapeutics, Cambridge, MA 02139, USA.

Vaishnavi Rajagopal (V)

CAMP4 Therapeutics, Cambridge, MA 02139, USA.

Cynthia Smith (C)

CAMP4 Therapeutics, Cambridge, MA 02139, USA.

Evan Cohick (E)

CAMP4 Therapeutics, Cambridge, MA 02139, USA.

Gavin Whissell (G)

CAMP4 Therapeutics, Cambridge, MA 02139, USA.

Mario Gamboa (M)

CAMP4 Therapeutics, Cambridge, MA 02139, USA.

Rutuja Pai (R)

CAMP4 Therapeutics, Cambridge, MA 02139, USA.

Alla Sigova (A)

CAMP4 Therapeutics, Cambridge, MA 02139, USA.

Iris Grossman (I)

CAMP4 Therapeutics, Cambridge, MA 02139, USA.

David Bumcrot (D)

CAMP4 Therapeutics, Cambridge, MA 02139, USA.

Kavitha Sasidharan (K)

Department of Molecular and Clinical Medicine, University of Gothenburg, SE-413 45 Gothenburg, Sweden.

Stefano Romeo (S)

Department of Molecular and Clinical Medicine, University of Gothenburg, SE-413 45 Gothenburg, Sweden.

Alfica Sehgal (A)

CAMP4 Therapeutics, Cambridge, MA 02139, USA.

Piero Pingitore (P)

Department of Molecular and Clinical Medicine, University of Gothenburg, SE-413 45 Gothenburg, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH